用oxo-azo化合物对口腔瘤点JAK STAT 3进行分子对接分析
Kaviya Karikalan1, Vishnu Priya Veeraraghavan1, Surya Sekaran2
1Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai - 600077, India.
Bioinformation
|September 18, 2023
概括
研究人员确定了Janus激酶信号转换器和转录3激活器 (JAK-STAT3) 信号传递的潜在抑制剂,以对抗口腔癌. 奥克萨化合物与JAK-1蛋白具有有前途的相互作用,表明其具有治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 简氏激酶信号转换器和转录3 (JAK-STAT3) 激活器信号与口腔癌的发展有关.
- 准JAK-STAT3通路为口腔癌提供了潜在的治疗策略.
- 识别新型抑制剂对于废除瘤发生至关重要.
研究的目的:
- 确定用于治疗口腔癌的JAK-STAT3信号传递的新型抑制剂.
- 为了评估已知的醇化合物与JAK-1蛋白质的结合潜力.
主要方法:
- 使用了分子对接模拟.
- 使用的是智人JAK-1蛋白 (PDB ID: 3EYG) 的3D晶体结构.
- 已知的氧醇化合物 (1-5) 与JAK-1蛋白质对接.
主要成果:
- 氧衍生物在JAK-1蛋白的结合部位内表现出有利的相互作用.
- 化合物1,4和5表现出最佳的结合特征与JAK-STAT3.3.
- 这些发现表明这些化合物的潜力作为JAK-STAT3抑制剂.
结论:
- 化合物1,4和5是抑制口腔癌中JAK-STAT3信号传递的有希望的候选物.
- 对这些牛醇衍生物的进一步研究可能会导致新的口腔癌疗法.
- 用这些化合物准JAK-STAT3可能会废止口腔癌的进展.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
610
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
8.5K
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
